Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
University of Utah
Would you use CTS5 to help you decide whether to offer prolonged adjuvant ET to HR+ breast cancer?
Answer from: Medical Oncologist at Community Practice
I would
Sign in or Register to read more
5507
Related Questions
Would a low genomic Mammaprint score deter you from offering adjuvant chemotherapy to a premenopausal woman with pT3N0 breast cancer?
Do you recommend using a ctDNA assay for a patient with HER2+ metastatic breast cancer in a continued CR to guide decision about whether to stop anti therapy?
What neoadjuvant chemotherapy do you suggest for a rapidly growing triple-negative breast cancer?
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
Would you consider adjuvant chemotherapy for a patient with HR+/HER2- breast cancer, luminal type A on Mammaprint, after knowing that the patient had a poor response to neoadjuvant endocrine therapy?
How would you approach dose modifications and/or frequency of lenalidomide in patients with advanced renal impairment (eGFR <30)?
In a patient with BRCA2 mutation and contralateral axillary recurrence of ER+ IDC with an ESR1 CCDC170 fusion on NGS testing, would you use standard adjuvant AI therapy or consider adjuvant SERD therapy (fulvestrant/elacestrant)?
How would you approach a patient with metastatic high grade neuroendocrine carcinoma of the breast which is HR+ HER2 negative?
How would you approach radiation for an elderly patient with pT2N1 TNBC s/p MRM and ALND who refused chemo-immunotherapy?
How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?